Final reports, quality assurance

The Principles of GLP require Quality Assurance to prepare and sign a statement, to be included with the final report, which specifies types of inspections and their dates, including the phase(s) of the study inspected, and the dates inspection results were reported to management and the Study Director and Principal Investigator(s), if applicable . Thus, after having audited the final report of the study, and after having been satisfied with the way the raw data have been recorded and represented in the final report. Quality Assurance has to look at its own records to identify the respective activities performed in connection with the study in question. Quality Assurance has then to draw up a list of such activities with their dates and to include this list in the Quality Assurance statement. 

Therefore, if final, fully quality-assured individual study reports are not available at the time of IND submission, an integrated summary report of toxicological findings based... 

If the integrated summary is based upon unaudited draft reports, sponsors should submit an update to their integrated summary by 120 days after the start of the human studies identifying any differences found in the preparation of the final, fully quality-assured study reports and the information submitted in the initial integrated summary. If no differences were found, that should be stated in the integrated summary update. In addition, any new finding discovered during the preparation of the final, fully quality-assured individual study reports that could affect subject safety must be reported to the FDA as an IND safety report. 

These final reports should contain in the introduction any changes from those reported in the integrated summary. If there are no changes, that should be clearly stated at the beginning of the final fully quality-assured report. 

Toxicology Integrated Summary of toxicologic effects in animals and in uitro. In cases where species specificity may be of concern, the sponsor is encouraged to discuss the issue with the Agency. In the early phase of IND, the final fully quality-assured individual study reports may slow preparation and delay the submission of application. If the integrated summary is based on unaudited draft reports, the sponsor is required to submit an update by 120 days after the start of the human studies and identify the differences. Any new find-... 

You should consider obtaining internal and external quality assurance reviews of the study (to ferret out errors in modeling, data, etc.). Independent peer reviews of the QRA results can be helpful by presenting alternate viewpoints, and you should include outside experts (either consultants or personnel from another plant) on the QRA review panel. You should also set up a mechanism wherein disputes between QRA team members (e.g., technical arguments about safety issues) can be voiced and reconciled. All of these factors play an essential role in producing a defendable, high-quality QRA. Once the QRA is complete, you must formally document your response to the project team s final report and any recommendations it contains. 

A quality assurance program statement listing the types of inspections made and their dates, including the phases inspected, and the dates when any inspection results were reported to management, to the Study Director, and to any Principal Investigators, if applicable. This statement would also serve to confirm that the final report reflects the raw data. 

The Study Director is the pivotal person in any GLP study. The sponsor initiates the study and assigns a Study Director to act as the primary control point for all aspects of the study. The Processing Principle Investigator (PPI) acts as an agent of the Study Director and handles the processing phase of the study. The PPI reports directly to the Study Director, and quality assurance (QA) documents resulting from the processing phase are sent to the Study Director for approval. The Study Director has final say in all questions of compliance with GLP and interpretations of the protocol. The... 

The format of the final report from a study is closely defined and the Study Director is responsible for its production. The test item and name of the study must be clearly identified, along with the start and end date. It has to be accompanied by a statement from the Quality Assurance unit that the study and any critical aspects of the work have been conducted to the requirements of GLP principles. It will contain the names of all those involved with the study and their address this includes the Study Director, the Principal Investigator, and all the scientists... 

Quality assurance includes all the quality controls, the generation of expectations (acceptance limits) from the quality controls, plus a great number of other activities, such as (1) analyst training and certification (2) data review and evaluation (3) preparation of final reports of analysis (4) information given to clients about tests that are needed to fulfill regulatory requirements (5) use of the... 

The quality assurance unit (QAU) performs the quality assurance audit. This task is ongoing throughout the study and is the reason for the existence of the QAU. The QAU is the person (see definition of "person" in Box 7.4) designated to perform the quality assurance duties. Thus, the QAU inspects the study to assure integrity and that problems are brought to the attention of the study director. This unit also determines if unauthorized deviations from protocols and SOPs occurred and reviews the final report for accuracy. 

This cost estimate includes mobilization, materials, pile installation, joint flushing and sealing, labor, a quality assurance/quality control program, and a final report (D22932N, p. 18 personal communication with Waterloo Barrier, Inc., 1998). 

Finally, the departments responsible for the qualification and validation work should approve the completed report and the conclusion of the report should state if the outcome of the qualification and/or validation was considered successful. The final review is performed by the quality assurance department, which gives the approval of the report according to the company s quality assurance system [1]. 

The principles of GLP require an independent quality assurance (QA) program to ensure that the study is being conducted in compliance with GLP. The QA personnel cannot overlap with those of the study because of the potential conflict of interest, but they may be part-time staff if the size of the study does not warrant a full-time QA section. The responsibilities of the QA unit are to maintain copies of plans, standard operating procedures, and in particular the master schedule of the study, and to verily, in writing, that these conform to GLP. The QA unit is responsible for inspections and audits, which must be documented and the results made available to the study director and the principal investigator. The QA unit also signs off on the final report. Any problems discovered or corrective action that is recommended by the unit must be documented and followed up. 

At the completion of the documentation, a final report should be drafted to indicate the conclusion and acceptability of the installation. The final report must be approved by the departments that approved the protocol. These are likely to be engineering/technology, production quality assurance/quality control and operations, and the validation manager. Approval of the final report by the relevant departments makes the way clear for proceeding with operational testing. 

Quality Assurance is the system of monitoring, inspecting, and auditing which assures that the work is documented and conducted according to protocol and the laboratories standard operating procedures from the conception of a study to the review of the final report. 

Proper organization of the study management is necessary for an effective quality assurance program. Each study is directed by the scientist who will write the final report but may be assisted by a coordinator. The coordinator also usually assists the study director in designing the study. All questions about the trial during its conduct in the field go to the study director or the coordinator. 

Once the investigation has concluded, a written laboratory (for laboratory-generated errors) or formal investigation report should be prepared, reviewed, and approved by the proper disciplines. The final approval is usually relegated to the quality assurance department, but should at least be reviewed by all investigation participants for accuracy and completeness. The report should include, as a minimum, the following details ... 

Although the GLP and quality assurance processes and principles are critical for the maintenance of a toxicology study system that is valid and credible, it is unusual for findings in the unaudited draft toxicologic report of the completed studies to change during the production of the final, quality-assured individual study reports in ways important to determining whether use in humans is safe. 

---